Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 15.04 and traded as low as GBX 13. Scancell shares last traded at GBX 13.40, with a volume of 786,915 shares trading hands.
Scancell Stock Up 1.1%
The firm’s 50-day simple moving average is GBX 19.59 and its 200 day simple moving average is GBX 15.04. The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56. The stock has a market capitalization of £139.06 million, a P/E ratio of -24.36 and a beta of 0.74.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
